The PedsDocTalk Podcast

Did you know while hospitalization is uncommon, respiratory syncytial virus (RSV) is the leading cause of hospitalization for babies under 1? RSV season is typically fall – spring but can vary by local areas and today I'm sharing about a preventative antibody which can help protect against severe RSV lung infections. I'm joined by Shawn Johnson East and Dr. Natalie Barnett, Vice President of Clinical Research at Nanit, to discuss the importance of RSV protection for babies. They share personal experiences, including Shawn's family's journey with RSV, and offer expert insights on how parents can help protect their little ones during RSV season.  They join me to discuss:  How RSV is common and can be a serious virus for infants. Beyfortus (nirsevimab-alip) 50mg and 100mg Injection, a preventative antibody that helps give babies an extra layer of protection against severe RSV lung infection for babies under age 1 born during or entering their first RSV season and certain kids up to 24 months. Your child should not take Beyfortus if your child has a history of serious allergic reactions to nirsevimab-alip or any of the ingredients in Beyfortus. Beyfortus may not protect all children. That parenting can be scary but navigating the journey with monitors like Nanit, and knowledge of prevention measures for RSV can be empowering. To connect with Shawn Johnson East follow her on Instagram @shawnjohnson. Visit Nanit.com to see their products and learn more about their research. For more about Beyfortus visit http://beyfortus.com. Our podcasts are also now on YouTube. If you prefer a video podcast with closed captioning, check us out there and subscribe to PedsDocTalk TV. We love the sponsors that make this show possible! You can always find all the special deals and codes for all our current sponsors on the PedsDocTalk Podcast Sponsorships page of the website. INDICATION Beyfortus is a prescription medicine used to help prevent a serious lung disease caused by Respiratory Syncytial Virus (RSV) in: Newborns and babies under 1 year of age born during or entering their first RSV season. Children up to 24 months of age who remain at risk of severe RSV disease through their second RSV season. IMPORTANT SAFETY INFORMATION Your child should not take Beyfortus if your child has a history of serious allergic reactions to nirsevimab-alip or any of the ingredients in Beyfortus. Before your child receives Beyfortus, tell your healthcare provider about all of your child’s medical conditions, including if your child: has ever had a reaction to Beyfortus. has bleeding or bruising problems. If your child has a problem with bleeding or bruises easily, an injection could cause a problem. Tell your healthcare provider about all the medicines your child takes, including prescription and over-the- counter medicines, vitamins, and herbal supplements. Your infant should not receive a medicine called palivizumab if they have already received Beyfortus in the same RSV season. Serious allergic reactions have happened with Beyfortus. Get medical help right away if your child has any of the following signs or symptoms of a serious allergic reaction: swelling of the face, mouth, or tongue difficulty swallowing or breathing unresponsiveness bluish color of skin, lips, or under fingernails muscle weakness severe rash, hives, or itching The most common side effects of Beyfortus include rash and pain, swelling, or hardness at the site of your child’s injection. These are not all the possible side effects of Beyfortus. Call your healthcare provider if you have questions about side effects. Full Prescribing Information: https://products.sanofi.us/beyfortus/beyfortus.pdf Patient Information: https://products.sanofi.us/beyfortus/beyfortus_patient-info.pdf Learn more about your ad choices. Visit megaphone.fm/adchoices